Exelixis Inc. | Cash Flow

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Net Income before Extraordinaries
244,760.00
268,542.00
161,744.00
70,222.00
154,227.00
690,070
Depreciation, Depletion & Amortization
3,147.00
2,391.00
1,406.00
1,002.00
1,187.00
7,769
Other Funds
-
1,438.00
-
4,108.00
6,563.00
41,755
Funds from Operations
198,195.00
225,128.00
115,740.00
16,863.00
172,557.00
495,483
Changes in Working Capital
578.00
10,277.00
25,845.00
227,267.00
6,946.00
79,763
Net Operating Cash Flow
198,773.00
235,405.00
141,585.00
210,404.00
165,611.00
415,720
Capital Expenditures
2,171.00
474.00
447.00
1,703.00
21,143.00
Sale of Fixed Assets & Businesses
143.00
1,230.00
1,441.00
97.00
164.00
Purchase/Sale of Investments
135,196.00
133,363.00
49,083.00
214,442.00
56,774.00
Net Investing Cash Flow
144,351.00
146,330.00
50,077.00
216,048.00
35,795.00
Issuance/Reduction of Debt, Net
13,170.00
11,709.00
4,381.00
7,710.00
185,788.00
Net Financing Cash Flow
11,669.00
65,492.00
152,747.00
15,696.00
169,928.00
Net Change in Cash
66,091.00
23,583.00
61,239.00
10,052.00
31,478.00
Free Cash Flow
200,944.00
235,879.00
142,032.00
208,701.00
144,468.00
Other Sources
17,268.00
20,354.00
-
-
-
Change in Capital Stock
1,501.00
75,763.00
157,128.00
27,514.00
22,423.00
Other Uses
6,085.00
8,143.00
-
-
-

About Exelixis

View Profile
Address
1851 Harbor Bay
Parkway Alameda California 94502
United States
Employees -
Website http://www.exelixis.com
Updated 07/08/2019
Exelixis, Inc. is a biopharmaceutical company, which engages in the development, commercialization, and discovery of new medicines for the treatment of cancer. It offers products under the brands of Cometriq, Cabometyx, and Cotellic. The company was founded by Corey S.